appliedtherapeutics.com (APLT) Enterprise Value to EBITDA Ratio

Public company logo of appliedtherapeutics.com (APLT)

The stability of Applied Therapeutics (APLT) relies on regulatory approval of its primary drug for the therapy of rare metabolic pathologies. Applied Therapeutics (APLT) develops innovative medicines in the US, addressing the shortage of effective treatments. This price chart on the GURU.Markets platform shows that EV/EBITDA is 0.00. A commitment to ESG principles and strict bioethics in laboratories confirm high reliability and transparency in business management.

Applied Therapeutics Inc. - APLT Company Value to EBITDA (period 11/23/2025 - 02/16/2026)

Comprehensive metric breakdowns and analytics for Applied Therapeutics Inc. (APLT)

- current price and projected stock value:
Stock Price Applied Therapeutics, Inc.|APLT - Analyst Median Target
- market capitalization details:
Market Valuation Applied Therapeutics, Inc.|APLT - Full Business Value
- business book valuation details:
Book Value per Share Applied Therapeutics|APLT - Total Stockholders' Equity|Market Capitalization to Book Value Ratio appliedtherapeutics.com|APLT - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Applied Therapeutics|APLT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Applied Therapeutics|APLT - Company Aggregate Indebtedness|Debts to Book Capitalization Applied Therapeutics, Inc.|APLT - Company Long-Term Loans and Borrowings|Company Short-Term Debts Applied Therapeutics|Quick Liquidity appliedtherapeutics.com
- financial results and valuation multiples details:
APLT - Final Profit|Expected Profit Applied Therapeutics|APLT - Price to Earnings Ratio|Forward P/E Multiple Applied Therapeutics, Inc.|APLT - PEG Multiple|EV/EBITDA Multiple Applied Therapeutics, Inc.|APLT - Operating profit EBITDA|Earnings per share for the last twelve months Applied Therapeutics|APLT - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months appliedtherapeutics.com|APLT - Earnings per share trend in current year|Net earnings per share growth forecast for next year Applied Therapeutics
Fundamental valuation:Applied Therapeutics, Inc. APLT
Manufactured products of Applied Therapeutics

The stability of Applied Therapeutics (APLT) relies on the capital-intensive development of orphan drugs, where massive clinical trial expenditures create a high barrier to entry. The EV/EBITDA valuation multiple relates the total enterprise value, including debt, to operating profit, allowing investors to use this chart to distinguish market volatility from actual changes in fundamental value or the degradation of the company's assets.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Corp)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma)|KROS (kerostx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Kamada Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FULC (Fulcrum Corp)|ABEO: EV/EBITDA Multiple|Mereo BioPharma Group plc (MREO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix BioTherapeutics, Inc.|PLRX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rein Therapeutics, Inc. (RNTX)|Enterprise Value to EBITDA Ratio gelteq.com GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma)|EV/EBITDA Multiple Chemomab Therapeutics Ltd CMMB|SRx Health - EV/EBITDA Multiple|PLRZ - EV/EBITDA Multiple|zentaris.com (AEZS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio CYTH (Cyclo Therapeutics, Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma Inc.|reneopharma.com - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization COSCIENS Biopharma (CSCI)